Milatuzumab Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
BNOX | F | Bionomics Limited | 3.28 | |
STRO | F | Sutro Biopharma, Inc. | -2.79 |
Related Industries: Biotechnology
Related Stock Lists:
Antineoplastic Drugs
Cancer
Cancer Treatment
Clinical Medicine
Alzheimer's Disease
Antibodies
Anxiolytics
Autoimmune Disorders
Biology
Biopharmaceutical
Camidanlumab Tesirine
Central Nervous System Disorders
Cognitive Impairment
Drug Discovery
Drugs
Endometrial Cancer
Hodgkin Lymphoma
Immune Disorders
Immunogen
Immunology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
CNCR | D | Loncar Cancer Immunotherapy ETF | 1.21 | |
BTEC | C | Principal Healthcare Innovators Index ETF | 0.07 | |
IWC | B | iShares Microcap ETF | 0.05 | |
SMLF | B | iShares FactorSelect MSCI USA Small-Cap ETF | 0.02 | |
IWN | B | iShares Russell 2000 Value ETF | 0.02 |
Compare ETFs
Related Industries:
Biotechnology
Related Stock Lists:
Antineoplastic Drugs
Cancer
Cancer Treatment
Clinical Medicine
Alzheimer's Disease
Antibodies
Anxiolytics
Autoimmune Disorders
Biology
Biopharmaceutical
Camidanlumab Tesirine
Central Nervous System Disorders
Cognitive Impairment
Drug Discovery
Drugs
Endometrial Cancer
Hodgkin Lymphoma
Immune Disorders
Immunogen
Immunology
- Milatuzumab
Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).
Popular Now
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles